HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies

Bibliography

• McKenna RJ, Schwinn CP, Soong KY. Sarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone). An analysis of 552 cases. J Bone Joint Surg Am 1966;48-A:1-26
   Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 2009;115:1531-43
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125:229-34
   PubMed Web of Science ®Google Scholar
• Cancer Facts and Figures 2008. Atlanta: American Cancer Society, Inc., 2008
   Google Scholar
• Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LA, Smith MAS, Gurney JG, , editors, Cancer incidence and survival among children and adolescents: United States SEER program 1975 – 1995 (Pub #99-4649), SEER program. Bethesda, MD: National Cancer Institute; 1999. p. 99-110
   Google Scholar
• Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-89
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Miser AW, The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6
   PubMed Web of Science ®Google Scholar
• Eilber F, Giuliano A, Eckardt J, Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-6
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Horowitz M, Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res 1991;270:8-14
   PubMed Web of Science ®Google Scholar
• Whelan J, Seddon B, Perisoglou M. Management of osteosarcoma. Curr Treat Options Oncol 2006;7:444-55
   PubMedGoogle Scholar
• Patel SJ, Lynch JW Jr, Johnson T, Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol 2002;25:489-95
   PubMedGoogle Scholar
• Bacci G, Briccoli A, Ferrari S, Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001;37:2030-9
   PubMed Web of Science ®Google Scholar
• Zalupski MM, Rankin C, Ryan JR, Adjuvant therapy of osteosarcoma – a Phase II trial: Southwest Oncology Group study 9139. Cancer 2004;100:818-25
   PubMedGoogle Scholar
• Meyers PA, Schwartz CL, Krailo MD, Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children's Oncology Group. J Clin Oncol 2008;26:633-8
   PubMed Web of Science ®Google Scholar
• Chou AJ, Kleinerman ES, Krailo MD, Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009;115(22):5339-48
   Google Scholar
• Bacci G, Forni C, Longhi A, Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol 2007;96:118-23
   PubMed Web of Science ®Google Scholar
• Rodriguez-Galindo C, Shah N, McCarville MB, Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970 – 2000). Cancer 2004;100:1928-35
   PubMedGoogle Scholar
• Grimer RJ, Sommerville S, Warnock D, Management and outcome after local recurrence of osteosarcoma. Eur J Cancer 2005;41:578-83
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776-90
   PubMed Web of Science ®Google Scholar
• Bargmann CI, Weinberg RA. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc Natl Acad Sci USA 1988;85:5394-8
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, Peterse JL, Mooi WJ, Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45
   PubMed Web of Science ®Google Scholar
• Cirisano FD, Karlan BY. The role of the HER-2/neu oncogene in gynecologic cancers. J Soc Gynecol Investig 1996;3:99-105
   PubMedGoogle Scholar
• Bongiorno PF, Whyte RI, Lesser EJ, Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg 1994;107:590-5
   PubMed Web of Science ®Google Scholar
• Onda M, Matsuda S, Higaki S, ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 1996;77:71-8
   PubMed Web of Science ®Google Scholar
• Gorlick R, Huvos AG, Heller G, Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17:2781-8
   PubMed Web of Science ®Google Scholar
• Zhou H, Randall RL, Brothman AR, Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25:27-32
   PubMed Web of Science ®Google Scholar
• Fellenberg J, Krauthoff A, Pollandt K, Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 2004;84:113-21
   PubMed Web of Science ®Google Scholar
• Akatsuka T, Wada T, Kokai Y, ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94:1397-404
   PubMed Web of Science ®Google Scholar
• Ferrari S, Bertoni F, Zanella L, Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004;100:1936-42
   PubMed Web of Science ®Google Scholar
• Bakhshi S, Gupta A, Sharma MC, Her-2/neu, p-53, and their coexpression in osteosarcoma. J Pediatr Hematol Oncol 2009;31:245-51
   PubMedGoogle Scholar
• Scotlandi K, Manara MC, Hattinger CM, Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005;41:1349-61
   PubMed Web of Science ®Google Scholar
• Maitra A, Wanzer D, Weinberg AG, Ashfaq R. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 2001;92:677-83
   PubMed Web of Science ®Google Scholar
• Kilpatrick SE, Geisinger KR, King TS, Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 2001;14:1277-83
   PubMed Web of Science ®Google Scholar
• Thomas DG, Giordano TJ, Sanders D, Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002;8:788-93
   PubMed Web of Science ®Google Scholar
• Hughes DP, Thomas DG, Giordano TJ, Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004;64:2047-53
   PubMed Web of Science ®Google Scholar
• Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004;40:963-70
   PubMed Web of Science ®Google Scholar
• Somers GR, Ho M, Zielenska M, HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 2005;8:525-32
   PubMed Web of Science ®Google Scholar
• Willmore-Payne C, Holden JA, Zhou H, Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions. Arch Pathol Lab Med 2006;130:691-8
   PubMed Web of Science ®Google Scholar
• Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7
   PubMed Web of Science ®Google Scholar
• Gancberg D, Lespagnard L, Rouas G, Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 2000;113:675-82
   PubMed Web of Science ®Google Scholar
• Roychowdhury DF, Tseng A Jr, Fu KK, New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer 1996;77:1419-26
   PubMed Web of Science ®Google Scholar
• Coombs LM, Pigott DA, Sweeney E, Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991;63:601-8
   PubMed Web of Science ®Google Scholar
• Kay EW, Mulcahy H, Walsh CB, Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994;25:455-61
   PubMed Web of Science ®Google Scholar
• Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995;76:1643-54
   PubMedGoogle Scholar
• Tubbs RR, Pettay JD, Roche PC, Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-21
   PubMed Web of Science ®Google Scholar
• Hughes DP, Thomas DG, Giordano TJ, Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 2006;46:614-23
   PubMed Web of Science ®Google Scholar
• Gorlick R, Kolb EA, Houghton PJ, Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009;53:594-8
   PubMedGoogle Scholar